RAYSUT-CEMENT-COMPANY
17.5.2021 14:01:06 CEST | Business Wire | Press release
In a significant endorsement that will support exports to European Union (EU) markets, Oman’s largest cement manufacturer, Raysut Cement Company (RCC), has received CE and NF certifications, two stringent global quality norms validating RCC’s adherence to EU standards in cement production.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005501/en/
The Muscat Stock Market (MSM)-listed RCC said the certifications come at a time when it is expanding exports to newer global markets. Currently, 50 per cent of the company’s output is exported to East Africa, India, Maldives, South Africa, and Indian Ocean islands.
“We consider CE and NF certifications a testimony to our commitment to constantly improve product quality and processes in line with rigorous global safety, quality and environmental regulations,” said Group CEO, Joey Ghose.
The CE (Conformité Européenne) mark, formerly EC mark, is mandatory for selling certain products in the European Economic Area (EEA) since 1985. The NF Mark from AFNOR certification entity is a French compliance norm that ensures product safety, quality, usage ability and performance.
“The certifications fit into our export strategy for newer geographies as the CE Mark that endorses compliance with EU’s health, safety and green regulations allows us to market our products in Iceland, Liechtenstein and Norway,” said Mr. Ghose.
Winning the certifications also coincided with RCC clinching a new export order from the Reunion Islands in the western Indian Ocean, and an annual contract has already been signed with Enterprise Audemard Group of the French island to ship 8,000 MT cement every month. The first shipment has been received by the party. RCC is also looking at setting up a grinding unit in Madagascar to leverage the 7-8 per cent Y-o-Y growth in that country’s market.
RCC has a current output of 6 million metric tonnes of cement, slated to increase to 10 million by 2022, and later to 22 million tonnes. Mr. Ghose said the COVID-19 pandemic has thrown a major challenge to the business, but RCC was facing it successfully with no change in leadership or vision.
Recently, RCC had won certifications from other parts of the world, boosting its export scope. These are from BIS (Bureau of Indian Standards), enabling it to stabilize its presence in India, and from SABPS (South African All Brothers Products and Systems) to help RCC leverage the South African market.
Mr. Salim bin Ahmed bin Alawi Al Ibrahim, Acting Deputy Group CEO of RCC said: “The cement now produced at RCC’s Salalah plant has accomplished the strictest environmental criterion of Hexavalent Chromium (Cr6+) content of less than two parts per million. The NF certification also opens up new market opportunities and we are now introducing a superior quality cement brand to the French colonies in the Indian Ocean Reunion Islands.”
Last year RCC won the ‘CEO of the Year’ honour for its Group CEO Mr. Joey Ghose, at both the Oman Best Employer Awards and GCC Best Employer Awards from Employer Branding Institute, which reinforced the company’s excellence across leadership, health and safety, technology, training and talent management.
“We regularly train our employees through on-the-job and by sending them overseas to upgrade their skills. This training helps us strictly implement quality, environmental and safety norms at our production facilities to improve our products in line with global demand,” added Mr. Al Ibrahim.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
